Future Directions in mCRPC

Opinion
Video

Panelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while emphasizing the importance of ongoing education for community oncologists to stay updated on these changes.

  • How do you see the treatment landscape for mCRPC evolving in the coming years?
  • What advice would you offer community oncologists for staying up to date with the rapidly changing field of mCRPC management?
Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Shyam Natarajan, PhD, answers a question during a Zoom video interview
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Illustration of prostate cancer | Image Credit: © Dr_Microbe - stock.adobe.com
Related Content
PREVENT trial: Transperineal biopsy lowers risk of infection vs transrectal biopsy

PREVENT trial: Transperineal biopsy lowers risk of infection vs transrectal biopsy

Hannah Clarke
September 20th 2024
Article

No patients in the transperineal cohort experienced an infection, compared with 1.6% of patients in the transrectal cohort.

Dr. Murphy on increasing diversity in cancer clinical trials

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
February 29th 2024
Podcast

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

PEACE-1 ancillary study: Biomarkers predict prognosis but not abiraterone benefit in mCSPC

PEACE-1 ancillary study: Biomarkers predict prognosis but not abiraterone benefit in mCSPC

Hannah Clarke
September 17th 2024
Article

Patients with at least 1 NE-positive marker were shown to have a worsened rPFS and OS.

Dr. Schwen on focal therapies for prostate cancer

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
January 11th 2024
Podcast

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

Radium223, chemotherapy improves mCRPC quality of life in phase 2 RAPSON

Radium223, chemotherapy improves mCRPC quality of life in phase 2 RAPSON

Kevin Kunzmann
September 16th 2024
Article

New data from ESMO 2024 support an initial dose of Radium223 prior to chemotherapy among patients with mCRPC.

SPLASH: 177Lu-PNT2002 achieves phase 3 outcomes for mCRPC

SPLASH: 177Lu-PNT2002 achieves phase 3 outcomes for mCRPC

Kevin Kunzmann
September 16th 2024
Article

New findings from the open-label SPLASH trial show patients with mCRPC achieved improved progression-free survival as well as response rates and antigen-specific reductions.

© 2024 MJH Life Sciences

All rights reserved.